Document is current

Any future updates will be listed below

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States

Crossref DOI link: https://doi.org/10.1007/s12325-022-02365-1

Published Online: 2023-01-17

Published Print: 2023-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark